All In Biotech

NDA 214662 · Mirum

Livmarli

Maralixibat Chloride · Oral

NovelBreakthrough therapyPriority reviewOrphan

CDER novel approval, Sep 29, 2021: To treat cholestatic pruritus associated with Alagille syndrome

Last checked: Nov 20, 2026Latest source record: Nov 8, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Sep 29, 2021

Approved uses

4

Original approval plus efficacy supplements

Registered trials

5

2 Phase 3, 0 recruiting

FAERS reports

1,002

284 serious, 21 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 10, 2025.

LIVMARLI is an ileal bile acid transporter (IBAT) inhibitor indicated for: • the treatment of cholestatic pruritus in patients 3 months of age and older with Alagille syndrome (ALGS). ( 1.1 ) • the treatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC). ( 1.2 ) o Limitations of Use: LIVMARLI is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of bile salt export pump (BSEP) protein. ( 14.2 ) 1.1 Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome LIVMARLI ® is indicated for the treatment of cholestatic pruritus in patients 3 months of age and older with Alagille syndrome (ALGS). 1.2 Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis LIVMARLI is indicated for the treatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC). Limitations of Use: LIVMARLI is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of bile salt export pump (BSEP) protein [see Clinical Studies (14.2) ] .

Mechanism: Maralixibat is a reversible inhibitor of the ileal bile acid transporter (IBAT). It decreases the reabsorption of bile acids (primarily the salt forms) from the terminal ileum . Pruritus is a common symptom in patients with ALGS or PFIC and the pathophysiology of pruritus in patients with ALGS or PFIC is not completely understood. Although the complete mechanism by which maralixibat improves pruritus in ALGS or PFIC patients is unknown, it may involve inhibition of the IBAT, which results in decreased reuptake of bile salts, as observed by a decrease in serum bile acids [see Clinical...

Therapeutic areas: Rare and genetic disease · Gastroenterology and liver

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 24, 2024 Supplement 10 · Efficacy OrphanLetterLabel
  • Mar 13, 2024 Supplement 5 · Efficacy OrphanLetterLabel
  • Mar 13, 2023 Supplement 4 · Efficacy · priority review OrphanLetterLabel
  • Sep 29, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
2 products under this application
  • LIVMARLI · MARALIXIBAT CHLORIDE EQ 9.5MG BASE/ML · SOLUTION, ORAL · Prescription
  • LIVMARLI · MARALIXIBAT CHLORIDE EQ 19MG BASE/ML · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Maralixibat Chloride" as an intervention, any sponsor and status, largest first.

All 5 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pruritus258
  • off label use120
  • liver transplant103
  • diarrhoea101
  • drug ineffective83
  • hepatic enzyme increased78
  • alanine aminotransferase increased67
  • blood bilirubin increased64
  • aspartate aminotransferase increased59
  • bile acids increased53
  • jaundice44
  • vomiting41

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20212
2022336
2023199
2024147
2025163
2026155

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Livmarli (Maralixibat Chloride)

2024 spending

$7.9M

Beneficiaries

n/a

64 claims

Per beneficiary

n/a

$1,829.32 per unit

View as table
YearSpending
2020$0
2021$0
2022$1,784,094
2023$3,899,017
2024$7,900,834

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Mirum

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.